Next Oncology

Fairfax, Virginia 22031

24 studies enrolling now · 46 studies all time

What they study most

Advanced Breast Cancer, Advanced Cancer, Advanced Colorectal Cancer, Advanced Lung Carcinoma, Advanced Metastatic Castration Resistant Prostate Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Solid Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors

Studies at this site

• Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors — Recruiting now
• A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours — Recruiting now
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer — Recruiting now
• A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors — Recruiting now
• A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
• STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas — Recruiting now
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) — Recruiting now
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer — Recruiting now
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer — Recruiting now
• A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors — Recruiting now
• A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors — Recruiting now
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations — Recruiting now
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) — Recruiting now
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients — Recruiting now
• A Study of TAK-505 in Adults With Solid Tumors — Recruiting now
• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer — Recruiting now
• Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors — Recruiting now
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies — Recruiting now
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors — Recruiting now
• A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
• PAS-004 in Patients With Advanced Solid Tumors — Recruiting now
• Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC — Recruiting now
• Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors — Recruiting now
• Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer — Stopped early
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications — Stopped early
• Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors — Stopped early
• Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors — Stopped early
• A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors — Stopped early
• Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors — Running, not enrolling
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer — Stopped early
• A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors — Running, not enrolling
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors — Running, not enrolling
• Study of TTX-MC138 in Subjects With Advanced Solid Tumors — Running, not enrolling
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors — Running, not enrolling
• Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors — Running, not enrolling
• SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation — Stopped early
• A Study of NDI 1150-101 in Patients With Solid Tumors — Running, not enrolling
• Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types — Stopped early
• A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors — Status unconfirmed
• A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer — Status unconfirmed
• Study of ASN004 in Patients With Advanced Solid Tumors — Completed
• PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates — Completed
• Study to Investigate DRP-104 in Adults With Advanced Solid Tumors — Stopped early